phosphodiesterase type 5
Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies
... “phosphodiesterase type 5 inhibitors”, “PDE5 inhibitors”, “PDE5i”, “avanafil”, “lodenafil”, “mirodenafil”, “sildenafil”, “tadalafil”, “udenafil”, or “vardenafil”, combined with ...
10
The Analysis of Primer Gene of Phosphodiesterase Type 5 (PDE5) on Erectyle Dysfungction
... Backround: Erectile dysfunction (ED) is the inability of male reproductive organs within sexual intercourse caused by neurogenic and hormonal disord- ers. There are some causes of ED such as hypertension, stress, ...
13
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
... Another mechanism of the improvement of the improve- ment is the pharmacokinetic interactions between bosentan and sildenafil or tadalafil. Sildenafil is predominantly metab- olized by cytochrome P450 (CYP) 3A4 and ...
5
Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials
... ACEi: angiotensin converting enzyme inhibitors; ARBs: angiotensin II receptor blockers; BP: blood pressure; bpm: beats per minute; cAMP: cyclic adenosine monophosphate; cGMP: cyclic guanosine monophosphate; CI: ...
18
Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example
... Illegal goods are divided into counterfeit and imitation goods. Counterfeit goods look like the genuine goods, having the same shape, color, and embossing. Imitations are defined as illegal products that do not look like ...
8
Avanafil for treatment of erectile dysfunction: review of its potential
... Avanafil is a new medication in the phosphodiesterase type 5 inhibitor class. The manufacturers plan to market avanafil as the first agent in the second generation of this class with a more rapid ...
7
Cardiovascular Disease Risk Assessment and Treatment of Erectile Dysfunction in Men with Diabetes Mellitus
... of phosphodiesterase type 5 [PDE 5] inhibitors and vacuum erection devices while the second line modalities consist of intra-urethral suppository, intra-corporal injections and testosterone ...
7
Ocimum gratissimum Linn Leaves reduce the key enzymes activities relevant to erectile dysfunction in isolated penile and testicular tissues of rats
... phosphodiesterase type-5. Hence, the mitigation of phosphodiesterase-5 (PDE-5) can also be a therapeutic approach in the management of ED ...
10
Prostanoid therapies in the management of pulmonary arterial hypertension
... Choice of initial therapy for PAH depends on several factors, most importantly the WHO functional class of the patient. Similar to the New York Heart Association classifica- tion for congestive heart failure, WHO ...
13
Interpreting risk reduction in clinical trials for pulmonary arterial hypertension
... of phosphodiesterase type 5 inhibitors resulted in a lower RR compared to endothelin receptor antagonists (RR ...evaluating phosphodiesterase type 5 inhibitors were of shorter ...
6
In Silico Mapping of Essential Residues in the Catalytic Domain of PDE5 Responsible for Stabilization of Its Commercial Inhibitors
... Abstract: Phosphodiesterase type 5 (PDE5) is an important enzyme associated with the hydrolysis of cyclic guanosine monophosphate (cGMP) to guanosine monophosphate ...
14
New horizons in pulmonary arterial hypertension therapies
... ABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease associated with vasoconstriction and vascular remodelling. There are three well-known pathways that contribute to the pathogenesis of PAH: endothelin, ...
12
Expression studies of recombinant cAMP-specific phosphodiesterase type 4
... for 5 minutes, centrifuged at 14 000 g for 3 seconds using a 5415C eppendorf microcentrifuge and either stored at - 20°C or loaded directly onto polyacrylamide gels after the addition o f DTT to a final ...
242
Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension
... EDTA, 11.1 glucose, pH 7.4). The perfusion pressure was monitored using a T-tube inserted between the pump and the inflow cannula that was connected to a pressure trans- ducer and a data acquisition system (Biopac ...
14
Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
... After the choice of a certain treatment has been made the question “do patients adhere to that treatment?” comes naturally. Most of the available adherence data concern sildenafi l and were obtained in a period of time ...
8
Hydroalcoholic Extract of Levisticum officinale Increases cGMP Signaling Pathway by Down-Regulating PDE5 Expression and Induction of Apoptosis in MCF-7 and MDA-MB-468 Breast Cancer Cell Lines
... therapeutic targets, which are directly involved in cancerous cell pathways, can be considered as a major challenge in cancer research [5,6] . A novel cancer-related marker is phosphodiesterase (PDE) enzyme. The ...
7
RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity
... Figure 8. Protective effect of RhoBTB1 on Ang-II–induced hypertension. (A and B) Relative mRNA expression of RhoBTB1 was determined by qPCR in aorta from control (A) or S-RhoBTB1 (B) mice after injection of vehicle (corn ...
16
Characterization of magnesium requirement of human 5' tyrosyl DNA phosphodiesterase mediated reaction
... × 5 s) on ice at full power using a Braun-Sonic U with a 10 minute gap between the two ...of 5-sub oligonucleotide in the presence of different concentration of MgCl2 and EDTA for 10 min at 37°C in an assay ...
7
Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy
... the only regimen achieving any significant impact. Multiple predefined subgroups were also analyzed to compare 6MWD distance from baseline to week 16. Significant improvements in 6MWD were observed in treatment-naive ...
11
Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver
... Nitric oxide (NO) plays a crucial role in hepatic microvas- cular blood flow under physiological conditions [1-5]. Hepatic vascular resistance is regulated on the one hand by contraction or relaxation of smooth ...
10